39.51

0.51% -0.1437

Vera Therapeutics Inc (VERA)

Overview News Price History Option Chain Financials Discussions Forecast

Vera Therapeutics Inc stock is traded at $39.51, with a volume of 112.85K. It is down -0.51% in the last 24 hours and down -3.67% over the past month. Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Previous Close:

$39.65

Open:

$38.93

24h Volume:

112.85K

Relative Volume:

0.09

Market Cap:

$2.82B

Revenue:

Net Income/Loss:

$-218.28M

P/E Ratio:

-11.03

EPS:

-3.5803

Net Cash Flow:

$-186.55M

1W Performance:

-6.85%

1M Performance:

-3.67%

6M Performance:

+63.07%

1Y Performance:

+31.67%

1-Day Range:

$38.51

$39.80

1-Week Range:

$38.51

$41.70

52-Week Range:

$18.53

$56.05

Vera Therapeutics Inc Stock (VERA) Company Profile

Name

Vera Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

650-770-0077

Address

2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE

Employee

249

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

VERA's Discussions on Twitter

Compare VERA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VERA Vera Therapeutics Inc	39.59	2.83B	0	-218.28M	-186.55M	-3.5803
VRTX Vertex Pharmaceuticals Inc	469.50	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	770.26	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	730.28	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	325.49	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	295.04	33.09B	5.36B	287.73M	924.18M	2.5229

Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-25	Initiated	BofA Securities	Buy
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy
Feb-04-25	Initiated	Wolfe Research	Outperform
Jan-28-25	Initiated	Goldman	Buy
Nov-21-24	Initiated	Wells Fargo	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform
Nov-10-23	Upgrade	Jefferies	Hold → Buy
Aug-16-23	Initiated	Guggenheim	Buy
Jan-04-23	Downgrade	Jefferies	Buy → Hold
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral
Jul-12-22	Initiated	JP Morgan	Overweight
May-02-22	Initiated	H.C. Wainwright	Buy
Apr-19-22	Initiated	Wedbush	Outperform

View All

Vera Therapeutics Inc Stock (VERA) Latest News

09:42 AM

Vera Therapeutics adds Christopher Hite to board of directors - Investing.com India

09:42 AM

09:27 AM

Vera Therapeutics appoints Christopher Hite to board of directors - marketscreener.com

09:27 AM

09:01 AM

Vera Therapeutics Appoints Christopher Hite To Board Of Directors - TradingView

09:01 AM

09:00 AM

Royalty Pharma vice chair joins Vera board before potential IgA drug launch - Stock Titan

09:00 AM

08:22 AM

Q1 EPS Estimates for Vera Therapeutics Cut by HC Wainwright - MarketBeat

08:22 AM

Mar 03, 2026

Vera Therapeutics Files BLA for Atacicept in IgAN, Target Action Date July 7, 2026 - Intellectia AI

Mar 03, 2026